Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atorvastatin + donepezil
- Development stage
- Discontinued
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of atorvastatin (a statin medication) and donepezil (an acetylcholinesterase inhibitor). This combination was specifically studied in the LEADe (Lipitor's Effect in Alzheimer's Dementia) trial to test whether adding atorvastatin 80 mg daily would provide benefits for patients with mild to moderate Alzheimer's disease who were already receiving donepezil 10 mg daily as background therapy. The study found no significant differences in cognition or global function compared to donepezil alone.
02
Targets
AcetylcholinesteraseHMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)
Beyond the preview
Go deeper on atorvastatin + donepezil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atorvastatin + donepezil.